CN114075282A - Il-5的结合分子及其制备方法和应用 - Google Patents
Il-5的结合分子及其制备方法和应用 Download PDFInfo
- Publication number
- CN114075282A CN114075282A CN202010843501.1A CN202010843501A CN114075282A CN 114075282 A CN114075282 A CN 114075282A CN 202010843501 A CN202010843501 A CN 202010843501A CN 114075282 A CN114075282 A CN 114075282A
- Authority
- CN
- China
- Prior art keywords
- ser
- seq
- gly
- ala
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010002616 Interleukin-5 Proteins 0.000 title claims abstract description 117
- 102000000743 Interleukin-5 Human genes 0.000 title claims abstract description 117
- 238000000034 method Methods 0.000 title description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 20
- 102000018358 immunoglobulin Human genes 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 2
- 208000023514 Barrett esophagus Diseases 0.000 claims description 2
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000001969 hypertrophic effect Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 57
- 108020004414 DNA Proteins 0.000 description 28
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 28
- 150000001413 amino acids Chemical group 0.000 description 28
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 27
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 27
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 27
- 108010073969 valyllysine Proteins 0.000 description 27
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 25
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 25
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 25
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 22
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 22
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 22
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 22
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 21
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 20
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 20
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 19
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 18
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- GFDUZZACIWNMPE-KZVJFYERSA-N Thr-Ala-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O GFDUZZACIWNMPE-KZVJFYERSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 14
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 14
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 14
- WDOCBGZHAQQIBL-IHPCNDPISA-N Phe-Trp-Ser Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 WDOCBGZHAQQIBL-IHPCNDPISA-N 0.000 description 14
- RGYDQHBLMMAYNZ-IHRRRGAJSA-N Tyr-Cys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=C(C=C1)O)N RGYDQHBLMMAYNZ-IHRRRGAJSA-N 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108010068488 methionylphenylalanine Proteins 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 13
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 13
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 13
- SLOYNOMYOAOUCX-BVSLBCMMSA-N Trp-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SLOYNOMYOAOUCX-BVSLBCMMSA-N 0.000 description 13
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 13
- 108010008355 arginyl-glutamine Proteins 0.000 description 13
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 12
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 12
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 description 12
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- KVGPYKUIHZJWGA-BQBZGAKWSA-N Cys-Met-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O KVGPYKUIHZJWGA-BQBZGAKWSA-N 0.000 description 11
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 11
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 11
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 11
- XWBJLKDCHJVKAK-KKUMJFAQSA-N Phe-Arg-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XWBJLKDCHJVKAK-KKUMJFAQSA-N 0.000 description 11
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 11
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 11
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 11
- 108010047857 aspartylglycine Proteins 0.000 description 11
- 108010089804 glycyl-threonine Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 108010009962 valyltyrosine Proteins 0.000 description 11
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 10
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 10
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 description 10
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 10
- YEKYGQZUBCRNGH-DCAQKATOSA-N His-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CO)C(=O)O YEKYGQZUBCRNGH-DCAQKATOSA-N 0.000 description 10
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 10
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 10
- 101150011375 Tab2 gene Proteins 0.000 description 10
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 10
- DKDHTRVDOUZZTP-IFFSRLJSSA-N Thr-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DKDHTRVDOUZZTP-IFFSRLJSSA-N 0.000 description 10
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 10
- 108010051242 phenylalanylserine Proteins 0.000 description 10
- 108010048818 seryl-histidine Proteins 0.000 description 10
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 9
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 9
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 9
- DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 9
- MHQXIBRPDKXDGZ-ZFWWWQNUSA-N Met-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@@H](N)CCSC)C(O)=O)=CNC2=C1 MHQXIBRPDKXDGZ-ZFWWWQNUSA-N 0.000 description 9
- 210000003979 eosinophil Anatomy 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 108091006020 Fc-tagged proteins Proteins 0.000 description 8
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 8
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 8
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 8
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 8
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 8
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 8
- 108010013835 arginine glutamate Proteins 0.000 description 8
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 7
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 description 7
- CNBIWHCVAZHRBI-IHRRRGAJSA-N Cys-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CS)N CNBIWHCVAZHRBI-IHRRRGAJSA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- GLJZDMZJHFXJQG-BZSNNMDCSA-N Phe-Ser-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLJZDMZJHFXJQG-BZSNNMDCSA-N 0.000 description 7
- UGDMQJSXSSZUKL-IHRRRGAJSA-N Pro-Ser-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O UGDMQJSXSSZUKL-IHRRRGAJSA-N 0.000 description 7
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 7
- OMRWDMWXRWTQIU-YJRXYDGGSA-N Thr-Tyr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N)O OMRWDMWXRWTQIU-YJRXYDGGSA-N 0.000 description 7
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 7
- 108010015792 glycyllysine Proteins 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 6
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 6
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- TVYMKYUSZSVOAG-ZLUOBGJFSA-N Cys-Ala-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O TVYMKYUSZSVOAG-ZLUOBGJFSA-N 0.000 description 6
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 6
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DEFGUIIUYAUEDU-ZPFDUUQYSA-N Lys-Asn-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DEFGUIIUYAUEDU-ZPFDUUQYSA-N 0.000 description 6
- FRWZTWWOORIIBA-FXQIFTODSA-N Met-Asn-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FRWZTWWOORIIBA-FXQIFTODSA-N 0.000 description 6
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 6
- DLZKEQQWXODGGZ-KWQFWETISA-N Tyr-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KWQFWETISA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 6
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 5
- 108010002386 Interleukin-3 Proteins 0.000 description 5
- 102000000646 Interleukin-3 Human genes 0.000 description 5
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 5
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 5
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 5
- IHAPJUHCZXBPHR-WZLNRYEVSA-N Thr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N IHAPJUHCZXBPHR-WZLNRYEVSA-N 0.000 description 5
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 5
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- WYPUMLRSQMKIJU-BPNCWPANSA-N Ala-Arg-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WYPUMLRSQMKIJU-BPNCWPANSA-N 0.000 description 4
- CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 4
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 4
- FVNAUOZKIPAYNA-BPNCWPANSA-N Ala-Met-Tyr Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FVNAUOZKIPAYNA-BPNCWPANSA-N 0.000 description 4
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 4
- FAUPLTGRUBTXNU-FXQIFTODSA-N Asp-Pro-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O FAUPLTGRUBTXNU-FXQIFTODSA-N 0.000 description 4
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 4
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 4
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 4
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 4
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 4
- VDCGPCSLAJAKBB-XIRDDKMYSA-N Trp-Ser-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N VDCGPCSLAJAKBB-XIRDDKMYSA-N 0.000 description 4
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- KQESEZXHYOUIIM-CQDKDKBSSA-N Ala-Lys-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KQESEZXHYOUIIM-CQDKDKBSSA-N 0.000 description 3
- IYKVSFNGSWTTNZ-GUBZILKMSA-N Ala-Val-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IYKVSFNGSWTTNZ-GUBZILKMSA-N 0.000 description 3
- CPSHGRGUPZBMOK-CIUDSAMLSA-N Arg-Asn-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CPSHGRGUPZBMOK-CIUDSAMLSA-N 0.000 description 3
- NLRJGXZWTKXRHP-DCAQKATOSA-N Asn-Leu-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NLRJGXZWTKXRHP-DCAQKATOSA-N 0.000 description 3
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 3
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 3
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 3
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 3
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 3
- HXIDVIFHRYRXLZ-NAKRPEOUSA-N Ile-Ser-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)N HXIDVIFHRYRXLZ-NAKRPEOUSA-N 0.000 description 3
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 3
- RDFIVFHPOSOXMW-ACRUOGEOSA-N Leu-Tyr-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RDFIVFHPOSOXMW-ACRUOGEOSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MSSXKZBDKZAHCX-UNQGMJICSA-N Phe-Thr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O MSSXKZBDKZAHCX-UNQGMJICSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 3
- RNDWCRUOGGQDKN-UBHSHLNASA-N Trp-Ser-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RNDWCRUOGGQDKN-UBHSHLNASA-N 0.000 description 3
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 3
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 3
- CNNVVEPJTFOGHI-ACRUOGEOSA-N Tyr-Lys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNNVVEPJTFOGHI-ACRUOGEOSA-N 0.000 description 3
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000055228 human IL5 Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002796 luminescence method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 2
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 2
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 2
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 2
- KNMRXHIAVXHCLW-ZLUOBGJFSA-N Asp-Asn-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O KNMRXHIAVXHCLW-ZLUOBGJFSA-N 0.000 description 2
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 2
- TZOZNVLBTAFJRW-UGYAYLCHSA-N Asp-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N TZOZNVLBTAFJRW-UGYAYLCHSA-N 0.000 description 2
- DINOVZWPTMGSRF-QXEWZRGKSA-N Asp-Pro-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O DINOVZWPTMGSRF-QXEWZRGKSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 2
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 2
- KPJJOZUXFOLGMQ-CIUDSAMLSA-N Lys-Asp-Asn Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N KPJJOZUXFOLGMQ-CIUDSAMLSA-N 0.000 description 2
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 2
- PWPBGAJJYJJVPI-PJODQICGSA-N Met-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C(O)=O)=CNC2=C1 PWPBGAJJYJJVPI-PJODQICGSA-N 0.000 description 2
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 2
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 2
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 2
- UGGWCAFQPKANMW-FXQIFTODSA-N Ser-Met-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UGGWCAFQPKANMW-FXQIFTODSA-N 0.000 description 2
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FDQXPJCLVPFKJW-KJEVXHAQSA-N Thr-Met-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O FDQXPJCLVPFKJW-KJEVXHAQSA-N 0.000 description 2
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 2
- PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 description 2
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 2
- SDHZOOIGIUEPDY-JYJNAYRXSA-N Val-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 SDHZOOIGIUEPDY-JYJNAYRXSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000009172 bursting Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- VQBULXOHAZSTQY-GKCIPKSASA-N Ala-Trp-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VQBULXOHAZSTQY-GKCIPKSASA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 1
- DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 description 1
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241001456553 Chanodichthys dabryi Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- PRXCTTWKGJAPMT-ZLUOBGJFSA-N Cys-Ala-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O PRXCTTWKGJAPMT-ZLUOBGJFSA-N 0.000 description 1
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
- CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 1
- QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 description 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 1
- HILMIYALTUQTRC-XVKPBYJWSA-N Glu-Gly-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HILMIYALTUQTRC-XVKPBYJWSA-N 0.000 description 1
- QLNKFGTZOBVMCS-JBACZVJFSA-N Glu-Tyr-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QLNKFGTZOBVMCS-JBACZVJFSA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- BGVYNAQWHSTTSP-BYULHYEWSA-N Gly-Asn-Ile Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BGVYNAQWHSTTSP-BYULHYEWSA-N 0.000 description 1
- JUGQPPOVWXSPKJ-RYUDHWBXSA-N Gly-Gln-Phe Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JUGQPPOVWXSPKJ-RYUDHWBXSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- GWCJMBNBFYBQCV-XPUUQOCRSA-N Gly-Val-Ala Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O GWCJMBNBFYBQCV-XPUUQOCRSA-N 0.000 description 1
- BGZIJZJBXRVBGJ-SXTJYALSSA-N Ile-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N BGZIJZJBXRVBGJ-SXTJYALSSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- HONVOXINDBETTI-KKUMJFAQSA-N Lys-Tyr-Cys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CS)C(O)=O)CC1=CC=C(O)C=C1 HONVOXINDBETTI-KKUMJFAQSA-N 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
- ZWBCVBHKXHPCEI-BVSLBCMMSA-N Met-Phe-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N ZWBCVBHKXHPCEI-BVSLBCMMSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- APKRGYLBSCWJJP-FXQIFTODSA-N Pro-Ala-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O APKRGYLBSCWJJP-FXQIFTODSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102220487962 S-formylglutathione hydrolase_L54A_mutation Human genes 0.000 description 1
- GHPQVUYZQQGEDA-BIIVOSGPSA-N Ser-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N)C(=O)O GHPQVUYZQQGEDA-BIIVOSGPSA-N 0.000 description 1
- BIWBTRRBHIEVAH-IHPCNDPISA-N Ser-Tyr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O BIWBTRRBHIEVAH-IHPCNDPISA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- NJLQMKZSXYQRTO-FHWLQOOXSA-N Tyr-Glu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NJLQMKZSXYQRTO-FHWLQOOXSA-N 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002444 effect on eosinophils Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 102200133100 rs17173509 Human genes 0.000 description 1
- 102220059647 rs370499060 Human genes 0.000 description 1
- 102220124709 rs3816644 Human genes 0.000 description 1
- 102220054627 rs45495192 Human genes 0.000 description 1
- 102220118921 rs60695352 Human genes 0.000 description 1
- 102220074220 rs796051883 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5409—IL-5
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
本发明公开了IL‑5的结合分子及其制备方法和应用，涉及医药生物领域，所述结合分子包括以下互补决定区：CDR1的氨基酸序列选自如SEQ ID NO.43～49所示序列中的任意一种；CDR2的氨基酸序列选自如SEQ ID NO.50～56所示序列中的任意一种；CDR3的氨基酸序列选自如SEQ ID NO.57～62所示序列中的任意一种。该结合分子可以特异性结合IL‑5，并能够有效阻断IL‑5诱导的细胞增殖，可用于IL‑5相关疾病如自身免疫疾病的预防、诊断和/或治疗。
Description
技术领域
本发明涉及医药生物技术领域，具体而言，涉及针对IL-5的结合分子及其制备方法和应用。
背景技术
人白细胞介素5，又称Interleukin-5，或IL-5，其与IL-13和粒细胞-巨噬细胞集落刺激因子(G M-CSF)均是参与造血和炎症的细胞因子(Metcalf；1986)。所有三种细胞因子都会促进嗜酸性粒细胞的产生，功能发挥和细胞存活(Metcalf；1986)，因此，具有影响炎性疾病的能力，例如在哮喘、特应性皮炎和过敏性鼻炎中，嗜酸性粒细胞起主要的效应作用。
作为嗜酸性粒细胞特异性细胞因子的IL-5已经受到大多数研究者的注意，其中IL-5mRNA和蛋白质水平在来自症状性哮喘患者的肺组织和支气管肺泡灌洗液(BAL)中有提升(Fukuda等1994)。研究者还观察到IL-5水平与过敏原激发和疾病活动之间的相关性(Sur等，1996)。然而，显而易见的是，不仅IL-5，GM-CSF和IL-3也在哮喘中的嗜酸性粒细胞产生和活化中起作用，有证据表明GM-CSF和IL-3在过敏性炎症发生位置合成(Bagley等，1997b；Allen等，1997)。这些细胞因子的表达可能有助于增加浸润性嗜酸性粒细胞的总数和嗜酸性粒细胞活化的程度。还有一种可能，这些细胞因子对不同阶段的嗜酸性粒细胞浸润作用有作用。来自接受抗原攻击的患者的最新动力学数据显示，IL-5水平在攻击后第2～7天之间增加，而GM-CSF在第2天达到峰值，并且在第16天保持升高。
IL-5、GM-CSF和IL-3通过与细胞表面受体结合来刺激嗜酸性粒细胞和其他正常细胞和癌细胞，所述细胞表面受体包含配体特异性α链和由三种受体共有的链(βc)(Bagley等1997a)。与每个受体的α链结合是受体激活的最初步骤，然而，单独α链结合不足以发生活化。随后配体会招募βc，随后是一个具有两个主要功能结果的步骤：首先，它允许IL-5、GM-CSF和IL-3的结合变得基本上不可逆转；其次，它导致完全受体激活(Bagley等1997a)。由于βc是这些受体的主要信号传导成分，它的参与导致JAK-2，STAT-5和其他信号分子的激活，最终导致通常与IL-5相关的过多细胞活动，GM-CSF和IL-3刺激如嗜酸性粒细胞粘附，引发脱颗粒和细胞毒性，以及延长细胞活力(Bates等，1996)。
为了在体内阻断或拮抗嗜酸性粒细胞活化细胞因子的活性，研究者尝试了三种主要方法。其中一个利用针对牵连细胞因子的抗体。例如，IL-5的抗体被用于过敏原诱导的哮喘的动物模型中，并且这一方法已经显示出在预防嗜酸性粒细胞流入气道和支气管高反应性方面具有相对长效的作用(Mauser等，1995)。但是现在仍然缺乏亲和力高的，能特异性抗IL-5的抗体或以IL-5为靶点的药物，鉴于此，特提出本发明。
发明内容
本发明的目的在于提供IL-5的结合分子及其制备方法和应用。
本发明是这样实现的：
第一方面，实施例提供了IL-5的结合分子，其能够特异性结合IL-5且包含至少一个免疫球蛋白单一可变结构域，所述免疫球蛋白单一可变结构域包括互补决定区CDR1、CDR2和CDR3；
其中，CDR1的氨基酸序列选自如SEQ ID NO.43～49所示序列中的任意一种；CDR2的氨基酸序列选自如SEQ ID NO.50～56所示序列中的任意一种；CDR3的氨基酸序列选自如SEQ ID NO.57～62所示序列中的任意一种。
第二方面，本发明实施例提供了分离的核苷酸，其编码如前述实施例所述的IL-5的结合分子。
第三方面，本发明实施例提供了重组载体，其含有前述实施例所述的分离的核苷酸。
第四方面，本发明实施例提供了宿主细胞，其含有前述实施例所述的重组载体。
第五方面，本发明实施例提供了IL-5的结合分子的制备方法，其包括培养如前述实施例所述的宿主细胞，获得IL-5的结合分子。
第六方面，本发明实施例提供了用于结合IL-5蛋白的偶联物，其包括偶联组分，以及如前述实施例所述的IL-5的结合分子；
所述偶联组分与所述IL-5的结合分子偶联；所述偶联组分包括用于检测的标记物和/或化合物。
第七方面，本发明实施例提供了用于检测IL-5的试剂盒，其包括前述实施例所述的IL-5的结合分子。
第八方面，本发明实施例提供如前述实施例所述的IL-5的结合分子在制备用于治疗疾病且以I L-5为靶点的药物中的应用。
本发明具有以下有益效果：
本发明实施例提供了IL-5的结合分子及其制备方法和应用，该结合分子能够特异性结合IL-5且包含至少一个免疫球蛋白单一可变结构域，所述免疫球蛋白单一可变结构域包括互补决定区CDR1、CDR2和CDR3；其中，CDR1的氨基酸序列选自如SEQ ID NO.43～49所示序列中的任意一种；CD R2的氨基酸序列选自如SEQ ID NO.50～56所示序列中的任意一种；CDR3的氨基酸序列选自如SE Q ID NO.57～62所示序列中的任意一种。该结合分子可特异性结合IL-5，并能够有效阻断IL-5诱导的细胞增殖，可用于IL-5相关疾病的预防、诊断和/或治疗。
附图说明
为了更清楚地说明本发明实施例的技术方案，下面将对实施例中所需要使用的附图作简单地介绍，应当理解，以下附图仅示出了本发明的某些实施例，因此不应被看作是对范围的限定，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他相关的附图。
图1为实施例1中人源重组IL-5的蛋白质凝胶电泳分析结果；
图2为实施例1中针对IL-5重组蛋白的纳米抗体文库筛选后的富集情况；其中，P/N＝生物淘选中阳性孔洗脱下的噬菌体感染TG1细菌后生长的单克隆细菌数/阳性孔洗脱下的噬菌体感染TG1细菌后生长的单克隆细菌数，该参数在富集发生后会逐渐增大；I/E＝生物淘选中每轮加入阳性孔的噬菌体总量/生物淘选中每轮从阳性孔洗脱出的噬菌体总量，该参数在富集发生后会逐渐趋近于1；
图3为实施例2中抗体株1B3和2B3的人源化变体的分别比对结果；
图4为验证例1中从实施例1中获得的大肠杆菌表达的12株抗体与IL-5结合能力的分析结果；
图5为验证例2中Tab1和Tab2与IL-5结合量效曲线；
图6为验证例2对照抗体1(Tab1)和对照抗体2(Tab2)与中和IL-5诱导的TF-1细胞增殖量效曲线；
图7为验证例3中从实施例3中获得的特异性针对IL-5的Fc融合单域抗体中和IL-5诱导的TF-1增殖量效曲线；
图8为验证例3中从实施例3中获得的不同人源化的Fc融合单域抗体中和IL-5诱导的TF-1增殖量效曲线。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚，下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市售购买获得的常规产品。
名词定义
本文中的“单域抗体”，SdAb，是一种天然缺失轻链的抗体，该抗体只包含一个重链可变区(VHH)，也被称为纳米抗体。
本文中“人源化抗体”是指将目标抗体(如动物抗体)的重链可变区与人抗体的恒定区融合而得到的抗体，或将目标抗体的互补决定区(CDR1～3序列)移植至人抗体的可变区内，得到的抗体，或将目标抗体根据人抗体骨架区(FR1～4)的特征进行氨基酸的突变后获得的抗体。人源化抗体可用合成法或定点突变法。
本文中“双链抗体”，Diabody，是一种小分子的双价双特异性抗体片段，能同时识别2种抗原的抗体。Hollinger等将A抗原抗体的轻链可变区基因(VLA)与抗B抗原抗体的重链可变区(VHB)通过短肽分子连接；同样地，将VHA和VLB连接，将两组嵌合基因置于双顺反子的表达质粒中，构建成双链抗体的表达质粒，表达后，VLA-VHB与VHA-VLB交叉连接，形成双特异性抗体。在本申请中，双价抗体能识别的其中一种抗原为IL-5蛋白，另一种可识别的抗原可选自现有的任意一种抗原。
本文中“多价抗体”，又称多链抗体，是指一种通过改造抗体结构后(与双链抗体类似)，能够同时识别多种抗原的抗体(同双链抗体)，在本申请中，其能识别的其中一种抗原为IL-5蛋白。
本说明书中提到的“CDR”为抗体的互补决定区，抗体通常包含两个可变区，重链可变区和轻链可变区，重链可变区或轻链可变区通常包括3个CDRs。
实施方式
本发明实施例提供了IL-5的结合分子，其能够特异性结合IL-5且包含至少一个免疫球蛋白单一可变结构域，所述免疫球蛋白单一可变结构域包括互补决定区CDR1、CDR2和CDR3；
其中，CDR1的氨基酸序列选自如SEQ ID NO.43～49所示序列中的任意一种；CDR2的氨基酸序列选自如SEQ ID NO.50～56所示序列中的任意一种；CDR3的氨基酸序列选自如SEQ ID NO.57～62所示序列中的任意一种。
优选地，所述互补决定区CDR1、CDR2和CDR3的氨基酸序列如(1)～(13)中任一项所示；
(1)如SEQ ID No.43、56和58所示；
(2)如SEQ ID No.49、51和60所示；
(3)如SEQ ID No.47、56和57所示；
(4)如SEQ ID No.45、54和57所示；
(5)如SEQ ID No.46、50和61所示；
(6)如SEQ ID No.47、56和62所示；
(7)如SEQ ID No.48、56和57所示；
(8)如SEQ ID No.45、53和57所示；
(9)如SEQ ID No.44、55和57所示；
(10)如SEQ ID No.43、56和59所示；
(11)如SEQ ID No.43、52和59所示；
(12)如SEQ ID No.47、56和59所示；
(13)如SEQ ID No.47、52和59所示；
在可选的实施方式中，所述免疫球蛋白单一可变结构域还包括骨架区，所述骨架区包括FR1、FR2、FR3和FR4；单域抗体的结构为：FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4。
其中，所述FR1的氨基酸序列选自如SEQIDNo.63～68所示序列中的任意一种；所述FR2的氨基酸序列选自如SEQIDNo.69～72所示序列中的任意一种；所述FR3的氨基酸序列选自如SEQIDNo.73～86所示序列中的任意一种；所述FR4的氨基酸序列如SEQIDNo.87所示。
优选地，所述免疫球蛋白单一可变结构域的骨架区FR1、FR2和FR3的序列如下(14)～(28)中任一项所示；
(14)如SEQ ID No.65、72和85所示；
(15)如SEQ ID No.65、72和82所示；
(16)如SEQ ID No.64、71和86所示；
(17)如SEQ ID No.65、72和73所示；
(18)如SEQ ID No.65、72和84所示；
(19)如SEQ ID No.66、69和83所示；
(20)如SEQ ID No.68、72和76所示；
(21)如SEQ ID No.66、69和79所示；
(22)如SEQ ID No.63、72和85所示；
(23)如SEQ ID No.67、70和80所示；
(24)如SEQ ID No.65、72和78所示；
(25)如SEQ ID No.65、72和77所示；
(26)如SEQ ID No.67、70和81所示；
(27)如SEQ ID No.65、72和74所示；
(28)如SEQ ID No.65、72和75所示。
优选地，所述免疫球蛋白单一可变结构域为VHH。
优选地，所述VHH的氨基酸序列选自如SEQ ID No.1～12所示序列中的任意一种。
优选地，所述所述VHH为人源化的VHH。
优选地，所述人源化的VHH的序列选自如SEQ ID No.13～21所示序列中的任意一种。
优选地，所述结合分子还包含免疫球蛋白Fc区，所述免疫球蛋白Fc区与VHH相连。
优选地，所述免疫球蛋白Fc区是人免疫球蛋白Fc区；
优选地，所述人免疫球蛋白Fc区是人IgG4的Fc区。
本发明实施例提供了分离的核苷酸，其编码如前述任意实施方式所述的IL-5的结合分子。
优选地，所述核苷酸的序列选自如SEQ ID No.22～42所示序列中的任意一种。
本发明实施例提供了重组载体，其含有如前述任意实施方式所述的分离的核苷酸。在可选实施方式中，重组载体可以为质粒、噬菌体或病毒载体。
本发明实施例提供了宿主细胞，其含有如前述实施例所述的重组载体。在可选实施例中，宿主细胞可以为原核细胞或真核细胞。
本发明实施例提供了IL-5的结合分子的制备方法，其包括培养如前述实施例所述的宿主细胞，获得IL-5的结合分子。
需要说明的是，上述任意实施方式所述的结合分子可以通过人工合成的方式制备，也可先合成其编码基因，在进行生物表达得到。
本发明实施例还提供了用于结合IL-5蛋白的偶联物，其包括偶联组分，以及如前述任意实施方式所述的IL-5的结合分子，所述偶联组分与所述IL-5的结合分子偶联；所述偶联组分包括用于检测的标记物和/或化合物。
优选地，所述用于检测的标记物为放射性元素。
本发明实施例还提供了用于检测IL-5蛋白的试剂盒，其包括如前述任意实施方式所述的IL-5的结合分子。
此外，本发明实施例还提供了所述的IL-5的结合分子在制备用于治疗疾病且以IL-5为靶点的药物中的应用。
优选地，所述疾病选自：哮喘、过敏性皮炎、湿疹、关节炎、疱疹、慢性原发性荨麻疹、硬皮病、肥大性瘢痕、慢性阻塞性肺疾病、特应性皮炎、特发性肺纤维化、川崎病、镰状细胞病、格雷夫斯氏病、舍格伦综合征、自体免疫淋巴组织增生性综合征、自体免疫性溶血性贫血、巴雷特食管、自体免疫葡萄膜炎、结核病和肾病中的任意一种。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
抗IL-5蛋白的单域抗体的制备。
A、人源重组IL-5蛋白的表达载体的构建：
在NCBI中检索获得IL-5的编码序列，其收录号为NM_000879.2，该序列编码产生的氨基酸序列登录号为NP_000870.1。分别通过TMHMM和SMART网站对NP_000870.1对应的氨基酸序列进行蛋白跨膜区和胞外端的分析。分析结果显示，IL-5蛋白没有跨膜区，为分泌蛋白；全长134个氨基酸，其中1～19位为该蛋白的信号肽。利用基因合成的方式，将编码IL-5蛋白的20-134位氨基酸的核苷酸序列克隆到载体pcDNA3.4中。将构建好的载体进行Sanger测序，并比对原始序列，检测无误后，将该重组质粒进行批量抽提，去除内毒素，转染悬浮293F进行目的蛋白的表达和纯化，纯化后人源重组IL-5蛋白的SDS-PAGE分析结果如图1所示。
由图1可知，表达纯化的人源重组IL-5的蛋白纯度约90％，本实施例中获得的IL-5蛋白将用于骆驼的免疫和抗体筛选。
B、抗IL-5蛋白的单域抗体文库的构建：
将600μg步骤A中纯化获得的人源重组IL-5蛋白与等体积的弗氏完全佐剂混合，免疫一只内蒙古阿拉善双峰驼。免疫方式为每周免疫一次，共连续免疫7次。且除首次免疫外，其余6次均是采用300μg IL-5重组蛋白与弗氏不完全佐剂等体积混合进行动物免疫，使骆驼产生抗IL-5的抗体。
动物免疫结束后，抽取骆驼外周血淋巴细胞100mL并提取细胞的RNA。利用提取的总RNA合成cDNA，并通过套式PCR反应以cDNA为模板扩增VHH(重链抗体可变区)。然后，利用限制性内切酶分别酶切pMECS载体和VHH片段(扩增获得的)，然后将酶切后的片段和载体链接；并将连接后的片段点转化至感受态细胞TG1中，构建IL-5蛋白的噬菌体展示文库，并测定库容，文库(重组TG1细胞)的库容大小约为1×109。
C、抗IL-5蛋白的单域抗体的筛选：
取200μL步骤B获得的重组TG1细胞至2×TY培养基中培养，培养期间，加入40μL辅助噬菌体VCSM13侵染TG1细胞，并培养过夜以扩增噬菌体，次日利用PEG/NaCl沉淀噬菌体，离心收集扩增噬菌体，获得扩增后的噬菌体文库。
将稀释在NaHCO3(100mM pH 8.3)中的IL-5蛋白500μg偶联在酶标板上，4℃放置过夜，同时设立阴性对照孔；第2天加入200μL的3％的脱脂乳，室温封闭2h；封闭结束后，加入100μL扩增后噬菌体文库(大约2×1011个噬菌体颗粒)，室温作用1h；作用1小时后，用PBS+0.05％Tween-20洗5遍，以洗掉未结合的噬菌体；用终浓度为2.5mg/mL的胰蛋白酶将与IL-5蛋白特异性结合的噬菌体解离下，并感染处于对数生长期的大肠杆菌TG1细胞，37℃培养1h，产生并收集噬菌体用于下一轮的筛选，相同筛选过程重复1轮，逐步得到富集，当富集倍数达到10倍以上时，富集效果如图2和表1所示。
表1富集效果
| 第一轮 | 第二轮 | 第三轮 | |
| I/E | 8000 | 35.71428571 | 4 |
| P/N | 3.125 | 180.6451613 | 2500 |
由结果可知，第三轮富集P/N为2500，I/E为4。
D、用噬菌体的酶联免疫法筛选抗IL-5的特异性阳性克隆：
当富集倍数达到10倍以上时，从筛选获得的阳性克隆中挑选400个单菌落分别接种于含100μg/mL氨苄青霉素的TB培养基的96深孔板中，并设置空白对照，37℃培养至对数期后，加入终浓度为1mM的IPTG，28℃培养过夜。
利用渗透涨破法获得抗体粗提液；将人源重组IL-5蛋白分别释至100mM pH 8.3的NaHCO3中，并将100μg重组IL-5蛋白蛋白在酶标板(ELISA板)中4℃包被过夜；将获得的抗体粗提液取100μL转移至加入抗原(重组IL-5蛋白)的ELISA板上，室温孵育1h；用PBST洗去未结合的抗体，加入100μl经1:2000稀释后的Mouse anti-HA tag antibody(鼠抗HA抗体，Thermo Fisher)，在室温孵育1h；用PBST洗去未结合的抗体，加入100ul经1:20000稀释后的Anti-Rabbit HRP conjugat e(山羊抗兔辣根过氧化物酶标记抗体，购自于ThermoFisher)，在室温孵育1h；用PBST洗去未结合的抗体，加入辣根过氧化物酶显色液，37℃下反应15min后，加入中止液，于酶标仪上450nm波长处，读取吸收值；当样品孔OD值大于对照孔5倍以上时，判定为阳性克隆孔；将阳性克隆孔的菌转摇在含有100μg/μL氨苄青霉素的LB培养基中，以便提取质粒并进行测序。并根据序列比对软件Vector NTI分析各个克隆株的基因序列，把CDR1，CDR2，CDR3序列相同的株视为同一克隆株，而序列不同的株视为不同克隆株，最终获得特异性抗IL-5蛋白的单域抗体。单域抗体的氨基酸序列为FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4结构，构成整个VHH。获得的单域抗体重组质粒(阳性质粒，目的序列)可以在原核系统中进行表达，最终获得单域抗体蛋白。
E、IL-5蛋白的特异性单域抗体在宿主大肠杆菌中的纯化及表达：
将步骤D中测序分析所获得不同克隆株的阳性质粒(pMECS-VHH)电转化到大肠杆菌HB2151中，并将其涂布在LB+amp+glucose即含有氨苄青霉素和葡萄糖的培养平板上，37℃培养过夜；挑选单个菌落接种在5mL含有岸边青霉素的LB培养液中，37℃摇床培养过夜；接种1mL的过夜培养菌种至330mL TB培养液中，37℃摇床培养，培养到OD600nm值达到0.6-0.9时，加入1M IPTG，28℃摇床培养过夜；离心，收集大肠杆菌，利用渗透胀破法，获得抗体粗提液；通过镍柱亲和层析法纯化出抗体，纯化后的单域抗体(请参照表2)。
表2单域抗体的信息
备注：表2中，CDR1～3以及FR1～4对应的数字为其SEQ ID No.的编号。
实施例2
抗IL-5的单域抗体的人源化。
人源化方法采用蛋白质表面氨基酸人源化的方法及单域抗体人源化通用框架移植法完成。
人源化步骤为：对抗体株1B3和2B3进行同源建模，建模软件为Discovery Studio，参考同源序列为NbBcII10抗体(PDB编号为：3DWT)，并根据蛋白三维结构计算氨基酸的相对溶剂可及性。
VHH人源化通用框架移植法具体步骤如下：首先获取根据序列同源性设计完成的通用性人源化VHH框架h-NbBcII10FGLA(PDB编号为：3EAK)，该框架设计基于纳米抗体NbBcII10抗体(PDB编号为：3DWT)，参考人源抗体DP-47进行蛋白表面氨基酸人源化，并改造VHH序列框架2(frame work-2)的部分氨基酸FGLA完成。直接使用h-NbBcII10FGLA作为框架，将CDR分别替换为抗体株1B3，2B3的CDR区，完成抗体的人源化。
对抗体株1B3，2B3进行人源化，获得5种抗体株的人源化变体。表3和表4为这些人源化变体的序列编号以及其中的氨基酸变化，其中氨基酸残基编号比照Kabat编号。图3显示人源化序列的比对结果。
表3克隆1B3、2B3人源化变体的序列编号以及部分变体中的氨基酸变化
| S11L | A14P | S45A | E49G | R50L | G52A | S53V | L54A | S63A | |
| 1B3-V1 | √ | √ | √ | √ | √ | √ | √ | √ | |
| 1B3-V2 | √ | ||||||||
| 1B3-V3 | √ | ||||||||
| 1B3-V4 | √ | ||||||||
| 1B3-V5 | |||||||||
| 2B3-V1 | √ | √ | √ | √ | √ | √ | √ | √ | |
| 2B3-V2 | √ | ||||||||
| 2B3-V3 | √ | ||||||||
| 2B3-V4 | √ |
表4克隆1B3、2B3人源化变体的序列编号以及部分变体中的氨基酸变化
实施例3
F、IL-5蛋白的单域抗体的Fc融合蛋白的真核表达载体的构建：
将实施例1步骤D中筛选出来的单域抗体经Sanger测序得到其核苷酸序列；通过序列合成的方式将密码子优化后的上述核苷酸序列合成至改造的载体RJK-V4-hFC中。
RJK-V4-hFC是一种纳米抗体通用的目标载体，为一种在invitrogen商业化载体pCDNA3.4(载体资料链接：https://assets.thermofisher.com/TFS-Assets/LSG/manuals/pcdna3_4_topo_ta_cloning_kit_man.pdf)的基础上融合了人源IgG的重链编码序列(NCBIAccession No.:AB776838.1)中的Fc区段后改造而来的，即该载体包含了IgG重链的铰链区(Hinge)CH2和CH3区。具体改造方案如下：
选取pcDNA3.4上的限制性酶切位点XbaI和AgeI；在Fc片段编码序列的5’端和3’端通过重叠PCR的方式分别引入多克隆位点(MCS，Multiple Cloning Site)和6×His标签。使用分别带有XbaI和AgeI酶切位点的一对引物通过PCR的方式将上述片段扩增；用限制性内切酶XbaI和AgeI分别酶切pcDNA3.4和带有XbaI和AgeI酶切位点引物的扩增片段；将酶切后的载体和插入片段在T4连接酶的作用下连接，然后将连接产物转化至大肠杆菌，扩增，测序核实，获得重组真核表达载体。
将构建好的重组真核表达载体转化至DH5α大肠杆菌中，培养进行质粒大提，去除内毒素；将大提后的质粒再进行序列测序鉴定；将确定无误后的重组载体准备后续真核细胞转染表达。
G、IL-5蛋白的特异性单域抗体的Fc融合蛋白在悬浮Expi CHO-S细胞中表达：
转染前3天，以2.5×105/mL的浓度细胞传代和扩大培养ExpiCHO-STM细胞，计算出的所需的细胞体积，并转移至装有120mL(终体积)的ExpiCHOTM表达培养基的500mL摇瓶中；使细胞浓度达到约(4～6)×106活细胞/mL；在转染前一天，将ExpiCHO-STM细胞稀释浓度至3.5×106活细胞/mL，使细胞过夜培养；转染当天，测定细胞密度和活细胞百分比。转染之前细胞密度应达到约(7～10)×106活细胞/mL；用预热至37℃新鲜的ExpiCHOTM表达培养基将细胞稀释至6×106个活细胞/mL。计算出的所需的细胞体积转移至装有新鲜的已预热的100mL(终体积)的ExpiCHOTM表达培养基的500mL摇瓶中；使轻轻颠倒混匀ExpiFectamineTMCHO试剂，用3.7mL OptiPROTM培养基稀释ExpiFectamineTMCHO试剂，回荡或混匀；用冷藏的4mL OptiPROTM培养基稀释质粒DNA(步骤F中获得的)，回荡混匀；将ExpiFectamine CHO/质粒DNA复合物室温孵育3min，然后轻轻加入制备的细胞悬液中，加入过程中轻轻回荡摇瓶；将细胞在37℃、8％CO2、加湿的空气中震荡培养；转染后第1天(18-22小时后)添加600μl ExpiFectamineTMCHO Enhancer(增强子)和24mL ExpiCHO fee d(补料)。在转染后约8天(细胞活率低于70％)收集上清。
H、IL-5蛋白的单域抗体的Fc融合蛋白在悬浮293F细胞中的表达。
转染前3天以2.5×105/mL细胞传代和扩大培养293F细胞，计算出的所需的细胞体积转移至装有新鲜的已预热的120mL(终体积)的OPM-293CD05 Medium培养基的500mL摇瓶中。使细胞浓度达到约(2～3)×106活细胞/mL。转染当天，测定细胞密度和活细胞百分比。转染之前细胞密度应达到约(2～3)×106活细胞/mL。用预热的OPM-293CD05 Medium将细胞稀释至1×106个活细胞/mL。计算出所需的细胞体积转移至装有新鲜的已预热的100mL(终体积)的培养基的500mL摇瓶中。用4mL Opti-MEM培养基稀释PEI(1mg/mL)试剂，回荡或吹打混匀；用4mL Opt-MEM培养基稀释质粒DNA(步骤F中获得的)，回荡混匀，并用0.22um的滤头过滤。室温孵育5min。将稀释的PEI试剂加入稀释的DNA中，颠倒混匀。将PEI/质粒DNA复合物室温孵育15～20分钟，然后轻轻加入制备的细胞悬液中，加入过程中轻轻回荡摇瓶。将细胞在37℃、5％CO2、120rpm震荡培养。转染后第24h、72h添加5mL OPM-CHO PFF05补料。在转染后约7天(细胞活率低于70％)收集上清。
I、IL-5蛋白的单域抗体的Fc融合蛋白的纯化
将步骤G或H中获得Fc融合蛋白的表达上清用0.45μm的一次性滤头过滤除掉不可溶杂质；将滤液使用蛋白纯化仪进行亲和层析纯化，利用人源Fc融合蛋白与Protein A(蛋白A)结合的能力，使用偶联Protein A的琼脂糖填料进行纯化；将滤液通过1mL/分钟的流速流穿Protein A预装柱，该步骤中滤液中的目标蛋白会与填料结合；通过低盐和高盐缓冲液将柱上结合的杂质蛋白洗涤；用低pH缓冲液将柱上结合的目标蛋白进行洗脱；将洗脱液迅速加入pH9.0的Tris-HCl溶液，进行中和。
将上述中和后的蛋白溶液透析后，进行SDS-PAGE分析，确定蛋白纯度在95％以上，且浓度在0.5mg/mL以上后，低温保存备用。
验证例1
实施例1提供的IL-5蛋白的特异性单域抗体的结合量效曲线测定。
包被50μL 1μg/mL IL-5蛋白于酶标板上，4℃过夜。洗板；加入200μL5％牛奶，37℃封闭1h。获取实施例1提供的IL-5蛋白的特异性单域抗体(VHH)，将VHH稀释至2μg/mL，然后5倍梯度稀释抗体，共8个浓度梯度。洗板；加入50μL抗体，两复孔，37℃孵育1h。洗板；加入50μL鼠抗HA标签HRP二抗，37℃孵育30min。洗板(多洗几次)；加入50μL预先恢复常温的TMB，避光常温反应15min。加入50μL终止液(1N HCl)，酶标仪读数保存。绘制曲线，计算EC50，如图4和表5所示。
表5 EC50结果
验证例2
靶向人源IL-5蛋白的工具抗体(Toolantibody，Tab)的表达和纯化。
获取Tab1(对照抗体1)和Tab2(对照抗体2)，其中，Tab1为mepolizumab，序列来自专利US7982005B2，Tab2为reslizumab序列，来自专利US6056957。
将搜索到的Tab1和Tab2序列委托通用生物系统(安徽)有限公司进行哺乳动物细胞表达系统密码子优化，并分别克隆至pcDNA3.1载体。
经过抗性筛选，选择质粒阳性菌扩增，使用质粒中提试剂盒(Macherey Nagel,Cat#740412.50)抽提质粒。按照每100mL细胞加入100μg质粒(50μg重链+50μg轻链)，使用PEI在293F细胞(培养基：FreeStyle 293Expression medium,Thermo,Cat#12338026+F-68,Thermo,Cat#24040032)中瞬转表达；转染6～24h后加入5％体积的10％Peptone(Sigma,Cat#P0521-100G)，8％CO2 130rpm培养约7～8天；细胞活率降至50％时收取表达上清，使用ProteinA(GE，Cat#17-5438-02)重力柱纯化；PBS透析后，使用Nanodrop测定浓度，SEC鉴定纯度，间接ELISA验证结合能力；通过本方法获得的Tab抗体，浓度不小于2mg/ml，纯度大于94％，与IL-5蛋白(Novoprotein，Cat#CS33)结合EC50结果如图5和表6所示。
表6 EC50结果
| Tab1 | Tab2 | HlgG | |
| EC50 | 1.321 | 0.7574 | ～4.591 |
人源重组IL-5蛋白诱导的TF1细胞增殖以及工具抗体(Tab)中和增殖实验。
人源重组IL-5蛋白诱导的TF1细胞增殖实验：将复苏后传代3-4待次的TF-1细胞按10000个每孔铺入96孔板；将人源IL-5蛋白配置最高浓度为500ng/mL的溶液，并进行5倍梯度稀释；将梯度稀释好的IL-5蛋白溶液按细胞培养液的等体积加入细胞培养孔；孵育72h后，用发光法细胞活力检测试剂盒检测细胞活力；根据检测结果计算IL-5诱导TF-1细胞增殖的EC80浓度。
Tab中和人源IL-5诱导的TF1细胞增殖实验：将复苏后传代3-4待次的TF-1细胞按10000个每孔铺入96孔板；将Tab1和Tab2配制为10μg/mL的溶液，并进行5倍梯度稀释；将梯度稀释好的Tab与增殖实验中获得的EC80浓度的IL-5按1:1混合，制成混合液；将混合液按细胞培养液的等体积加入细胞培养孔；孵育72h后，用发光法细胞活力检测试剂盒检测细胞活力；根据检测结果计算Tab1和Tab2中和IL-5诱导TF-1细胞增殖的EC50浓度，结果如图6和表7所示。
表7 EC50结果
| Tab1 | Tab2 | HlgG | |
| EC50 | 0.2338 | 0.06639 | ～0.1323 |
抗IL-5蛋白的单域抗体的Fc融合蛋白中和IL-5诱导TF1细胞增殖的检测。
将复苏后传代3-4待次的TF-1细胞按10000个每孔铺入96孔板；将Tab1和Tab2以及实施例3-I提供的单域抗体的Fc融合蛋白配制为10μg/mL的溶液，并进行5倍梯度稀释；将梯度稀释好的Tab、单域抗体与增殖实验中获得的EC80浓度的IL-5蛋白按1:1混合，制成混合液；将混合液按细胞培养液的等体积加入细胞培养孔；孵育72h后，用发光法细胞活力检测试剂盒检测细胞活力；根据检测结果计算不同单域抗体中和IL-5诱导TF-1细胞增殖的EC50浓度，结果如图7～图8以及表8～表9所示。
表8 EC50结果
表9 EC50结果
IL-5结合分子的亲和动力学检测
SD缓冲液配制：取适量牛血清白蛋白和吐温20以1×PBS(pH7.4)溶解，使得牛血清白蛋白和吐温20质量(或体积)分数分别为0.1％和0.02％；将IL-5结合分子用SD缓冲液配制成10μg/mL的浓度；抗原工作液配制：抗原先以SD缓冲液配制成200nM，再按2倍梯度稀释，共设置5个浓度梯度，除此之外再设置一个SD缓冲液的空白对照；取适量浓度为0.1M的甘氨酸储备液，用去离子水稀释10倍，混匀，获得再生液；开启Octet 96及其配套电脑中DataAcquisiton软件，用擦镜纸取适量75％的乙醇清洁采集探头的底面和侧面，仪器预热15min以上；Sensor预湿：Sensor在实验开始前置于SD缓冲液中浸泡10分钟以上，待用，然后设定机器程序按照：基线→抗体→基线→结合抗原→解离抗原→再生传感器的步骤进行实验操作。
具体测定的IL-5结合分子的亲和动力学参数如表10所示。
表10克隆1B3、2B3及其人源化变体与IL-5亲和动力学结果
| 克隆名 | KD(M) | KD Error | Ka(1/Ms) | Ka Error | Kd(1/s) | Kd Error | X<sup>2</sup> | R<sup>2</sup> |
| Tab1 | 0.99E-09 | 6.49E-11 | 8.26E+04 | 4.50E+02 | 8.22E-05 | 5.34E-06 | 0.1917 | 0.9978 |
| 2B3-V2 | 2.06E-09 | 4.60E-11 | 1.97E+05 | 1.71E+03 | 4.06E-04 | 8.35E-06 | 0.102 | 0.9838 |
| 2B3 | 1.60E-09 | 4.03E-11 | 1.84E+05 | 1.35E+03 | 2.95E-04 | 7.11E-06 | 0.1618 | 0.9892 |
| 1B3-V2 | 1.02E-09 | 2.78E-11 | 1.80E+05 | 9.48E+02 | 1.84E-04 | 4.91E-06 | 0.0988 | 0.9941 |
| 1B3 | 0.88E-09 | 3.38E-11 | 1.49E+05 | 7.81E+02 | 1.32E-04 | 5.00E-06 | 0.1979 | 0.9954 |
结果显示，与工具抗体相比，克隆1B3的亲和动力学常数略小，其余克隆略大，但各个检测样品间的亲和动力学常数无明显差异，不具有统计学差异。
以上所述仅为本发明的优选实施例而已，并不用于限制本发明，对于本领域的技术人员来说，本发明可以有各种更改和变化。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
SEQUENCE LISTING
<110> 南京融捷康生物科技有限公司
<120> IL-5的结合分子及其制备方法和应用
<160> 87
<170> PatentIn version 3.5
<210> 1
<211> 120
<212> PRT
<213> 人工序列
<400> 1
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Lys Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 2
<211> 120
<212> PRT
<213> 人工序列
<400> 2
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Gln Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Lys Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 3
<211> 122
<212> PRT
<213> 人工序列
<400> 3
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Ala Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Leu Asp Leu Met
20 25 30
Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ala Gly
35 40 45
Ile Tyr Ser Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg
50 55 60
Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met
65 70 75 80
Asn Ser Leu Lys Pro Glu Asp Ala Ala Met Tyr Tyr Cys Ala Ala Lys
85 90 95
Val Ser Trp Tyr Gly Arg Trp Tyr Gln Ser Glu Thr Tyr Glu Tyr Trp
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 4
<211> 122
<212> PRT
<213> 人工序列
<400> 4
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Phe Ser
20 25 30
Thr Tyr Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu
35 40 45
Gly Ser Leu Ala Thr Ile Tyr Asp Gly Ser Thr Ala Tyr Ala Gly Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu
65 70 75 80
Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ala Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 5
<211> 120
<212> PRT
<213> 人工序列
<400> 5
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Lys Pro Ala Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Lys Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 6
<211> 120
<212> PRT
<213> 人工序列
<400> 6
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ser Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Gly Asn Ile Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 7
<211> 122
<212> PRT
<213> 人工序列
<400> 7
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Leu Asn Asp Val
20 25 30
Ser Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Glu Val
35 40 45
Ala Gly Ile Asp Ile Asp Gly Leu Ile Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Gln Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Ser Cys Ala
85 90 95
Ala Val Arg Leu Tyr Phe Ser Ser Ser Arg Asn Gln Tyr Lys Tyr Glu
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 8
<211> 122
<212> PRT
<213> 人工序列
<400> 8
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Phe Ser
20 25 30
Thr Tyr Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu
35 40 45
Gly Ser Leu Ala Thr Ile Tyr Asp Gly Ser Thr Ala Tyr Ala Gly Ser
50 55 60
Val Lys Gly Arg Phe Thr Val Ser Val Asp Asn Ala Lys Asn Ile Leu
65 70 75 80
Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ser Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 9
<211> 122
<212> PRT
<213> 人工序列
<400> 9
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Leu Asn Asp Val
20 25 30
Ser Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Glu Val
35 40 45
Ala Gly Ile Asp Ile Asp Gly Leu Ile Ser Tyr Ala Asp Pro Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Gln Asn Thr Met Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Ser Cys Ala
85 90 95
Ala Val Arg Leu Tyr Phe Ser Ser Ser Arg Asn Gln Tyr Lys Tyr Glu
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 10
<211> 122
<212> PRT
<213> 人工序列
<400> 10
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Thr Ser
20 25 30
Thr Tyr Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu
35 40 45
Gly Ser Leu Ala Thr Ile Tyr Asp Gly Ser Thr Ala Tyr Ala Gly Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu
65 70 75 80
Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ala Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 11
<211> 120
<212> PRT
<213> 人工序列
<400> 11
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ser Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Gly Ala Ile Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 12
<211> 120
<212> PRT
<213> 人工序列
<400> 12
Gln Val Gln Leu Val Glu Ser Glu Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ile Thr Ser Ser Thr Ala
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Gly Ser Ile Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 13
<211> 120
<212> PRT
<213> 人工序列
<400> 13
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val
35 40 45
Ala Ala Thr Ile Tyr Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 14
<211> 120
<212> PRT
<213> 人工序列
<400> 14
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Ala Ser Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 15
<211> 120
<212> PRT
<213> 人工序列
<400> 15
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Ala Ser Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95
Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 16
<211> 120
<212> PRT
<213> 人工序列
<400> 16
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Ala Ser Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 17
<211> 120
<212> PRT
<213> 人工序列
<400> 17
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Ala Ser Thr Ser
20 25 30
Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser
35 40 45
Leu Ala Thr Ile Tyr Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Leu Tyr Leu
65 70 75 80
Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp Gly Gln
100 105 110
Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 18
<211> 122
<212> PRT
<213> 人工序列
<400> 18
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Phe Ser
20 25 30
Thr Tyr Cys Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45
Ala Val Ala Ala Thr Ile Tyr Asp Gly Ser Thr Tyr Tyr Ala Gly Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp
100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 19
<211> 122
<212> PRT
<213> 人工序列
<400> 19
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Phe Ser
20 25 30
Thr Tyr Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu
35 40 45
Gly Ser Leu Ala Thr Ile Tyr Asp Ala Ser Thr Ala Tyr Ala Gly Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Leu
65 70 75 80
Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 20
<211> 122
<212> PRT
<213> 人工序列
<400> 20
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Phe Ser
20 25 30
Thr Tyr Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu
35 40 45
Gly Ser Leu Ala Thr Ile Tyr Asp Ala Ser Thr Ala Tyr Ala Gly Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Val Asp Asn Ala Lys Asn Ile Leu
65 70 75 80
Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr
85 90 95
Cys Ala Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 21
<211> 122
<212> PRT
<213> 人工序列
<400> 21
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Phe Ser
20 25 30
Thr Tyr Cys Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu
35 40 45
Gly Ser Leu Ala Thr Ile Tyr Asp Ala Ser Thr Ala Tyr Ala Gly Ser
50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu
65 70 75 80
Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp
100 105 110
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120
<210> 22
<211> 360
<212> DNA
<213> 人工序列
<400> 22
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atggcagcac cagctatgcg 180
gatagcgtga aaggccgttt taccattagc gtggataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgaaacc ggaagatacc gcgatgtatt attgcgcggc ggcgaaatat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 23
<211> 360
<212> DNA
<213> 人工序列
<400> 23
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atggcagcac cagctatgcg 180
gatagcgtga aaggccagtt taccattagc gtggataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgaaacc ggaagatacc gcgatgtatt attgcgcggc ggcgaaatat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 24
<211> 366
<212> DNA
<213> 人工序列
<400> 24
caggtgcagc tggtggaaag cggcggcggc agcgcgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa caccctggat ctgatggcgt ggtttcgtca ggcgccgggc 120
aaagaacgtg aaggcgtggc gggcatttat agcagcggca ccacctatta tgcggatagc 180
gtgaaaggcc gttttaccgt gagccgtgat aacgcgaaaa acaccgtgta tctgcagatg 240
aacagcctga aaccggaaga tgcggcgatg tattattgcg cggcgaaagt gagctggtat 300
ggccgttggt atcagagcga aacctatgaa tattggggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 25
<211> 366
<212> DNA
<213> 人工序列
<400> 25
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa cacctttagc tttagcacct attgcatggg ctggtttcgt 120
cagagcccgg gcaaagaacg tgaaggcagc ctggcgacca tttatgatgg cagcaccgcg 180
tatgcgggca gcgtgaaagg ccgttttacc attagcgtgg ataacgcgaa aaacattctg 240
tatctgcaga tgaacaacct gaaaccggaa gataccgcga tgtattattg cgcggcggcg 300
aaatattgca tgttttggag cgatccgagc tattggggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 26
<211> 360
<212> DNA
<213> 人工序列
<400> 26
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atggcagcac cagctatgcg 180
gatagcgtga aaggccgttt taccattagc gtggataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgaaacc ggcggatacc gcgatgtatt attgcgcggc ggcgaaatat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 27
<211> 360
<212> DNA
<213> 人工序列
<400> 27
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccagcagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atggcaacat tagctatgcg 180
gatagcgtga aaggccgttt taccattagc gtggataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgaaacc ggaagatacc gcgatgtatt attgcgcggc ggcgaaatat 300
tgcatgtttt ggagcgatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 28
<211> 366
<212> DNA
<213> 人工序列
<400> 28
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgtgg cgagcggcct gaccctgaac gatgtgagca tggcgtggtt tcgtcaggcg 120
ccgggcaaag aacgtgaaga agtggcgggc attgatattg atggcctgat tagctatgcg 180
gatagcgtga aaggccgttt taccattagc aaagataacg cgcagaacac cctgtatctg 240
cagatgaaca gcctgaaacc ggaagatacc gcgatgtata gctgcgcggc ggtgcgtctg 300
tattttagca gcagccgtaa ccagtataaa tatgaaggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 29
<211> 366
<212> DNA
<213> 人工序列
<400> 29
caggtgcagc tggtggaaag cggcggcggc agcgtgcagc cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa cacctttagc tttagcacct attgcatggg ctggtttcgt 120
cagagcccgg gcaaagaacg tgaaggcagc ctggcgacca tttatgatgg cagcaccgcg 180
tatgcgggca gcgtgaaagg ccgttttacc gtgagcgtgg ataacgcgaa aaacattctg 240
tatctgcaga tgaacaacct gaaaccggaa gataccgcga tgtattattg cgcgagcgcg 300
aaatattgca tgttttggag cgatccgagc tattggggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 30
<211> 366
<212> DNA
<213> 人工序列
<400> 30
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgtgg cgagcggcct gaccctgaac gatgtgagca tggcgtggtt tcgtcaggcg 120
ccgggcaaag aacgtgaaga agtggcgggc attgatattg atggcctgat tagctatgcg 180
gatccggtga aaggccgttt taccattagc aaagataacg cgcagaacac catgtatctg 240
cagatgaaca gcctgaaacc ggaagatacc gcgatgtata gctgcgcggc ggtgcgtctg 300
tattttagca gcagccgtaa ccagtataaa tatgaaggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 31
<211> 366
<212> DNA
<213> 人工序列
<400> 31
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa cacctttagc accagcacct attgcatggg ctggtttcgt 120
cagagcccgg gcaaagaacg tgaaggcagc ctggcgacca tttatgatgg cagcaccgcg 180
tatgcgggca gcgtgaaagg ccgttttacc attagcgtgg ataacgcgaa aaacattctg 240
tatctgcaga tgaacaacct gaaaccggaa gataccgcga tgtattattg cgcggcggcg 300
aaatattgca tgttttggag cgatccgagc tattggggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 32
<211> 360
<212> DNA
<213> 人工序列
<400> 32
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccagcagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atggcgcgat tagctatgcg 180
gatagcgtga aaggccgttt taccattagc gtggataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgaaacc ggaagatacc gcgatgtatt attgcgcggc ggcgaaatat 300
tgcatgtttt ggagcgatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 33
<211> 360
<212> DNA
<213> 人工序列
<400> 33
caggtgcagc tggtggaaag cgaaggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg tgagcggcat taccagcagc accgcgtgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atggcagcat tagctatgcg 180
gatagcgtga aaggccgttt taccattagc gtggataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgaaacc ggaagatacc gcgatgtatt attgcgcggc ggcgaaatat 300
tgcatgtttt ggagcgatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 34
<211> 360
<212> DNA
<213> 人工序列
<400> 34
caggtgcagc tggtggaaag cggcggcggc ctggtgcagc cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcaggcg 120
ccgggcaaag gcctggaagc ggtggcggcg accatttatg atggcagcac ctattatgcg 180
gatagcgtga aaggccgttt taccattagc cgtgataaca gcaaaaacac cctgtatctg 240
cagatgaaca gcctgcgtgc ggaagatacc gcggtgtatt attgcgcggc ggcgcgttat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca ccctggtgac cgtgagcagc 360
<210> 35
<211> 360
<212> DNA
<213> 人工序列
<400> 35
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atgcgagcac cagctatgcg 180
gatagcgtga aaggccgttt taccattagc cgtgataaca gcaaaaacat tctgtatctg 240
cagatgaaca acctgcgtgc ggaagatacc gcggtgtatt attgcgcggc ggcgcgttat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 36
<211> 360
<212> DNA
<213> 人工序列
<400> 36
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atgcgagcac cagctatgcg 180
gatagcgtga aaggccgttt taccattagc gtggataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgaaacc ggaagatacc gcgatgtatt attgcgcggc ggcgcgttat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 37
<211> 360
<212> DNA
<213> 人工序列
<400> 37
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atgcgagcac cagctatgcg 180
gatagcgtga aaggccgttt taccattagc cgtgataacg cgaaaaacat tctgtatctg 240
cagatgaaca acctgcgtgc ggaagatacc gcggtgtatt attgcgcggc ggcgcgttat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 38
<211> 360
<212> DNA
<213> 人工序列
<400> 38
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcat taccgcgagc accagctgca tgggctggtt tcgtcagagc 120
ccgggcaaag aacgtgaagg cagcctggcg accatttatg atggcagcac cagctatgcg 180
gatagcgtga aaggccgttt taccattagc cgtgataaca gcaaaaacat tctgtatctg 240
cagatgaaca acctgcgtgc ggaagatacc gcggtgtatt attgcgcggc ggcgcgttat 300
tgcatgtttt ggagccatcc gagctattgg ggccagggca cccaggtgac cgtgagcagc 360
<210> 39
<211> 366
<212> DNA
<213> 人工序列
<400> 39
caggtgcagc tggtggaaag cggcggcggc ctggtgcagc cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa cacctttagc tttagcacct attgcatggg ctggtttcgt 120
caggcgccgg gcaaaggcct ggaagcggtg gcggcgacca tttatgatgg cagcacctat 180
tatgcgggca gcgtgaaagg ccgttttacc attagccgtg ataacagcaa aaacaccctg 240
tatctgcaga tgaacagcct gcgtgcggaa gataccgcgg tgtattattg cgcggcggcg 300
cgttattgca tgttttggag ccatccgagc tattggggcc agggcaccct ggtgaccgtg 360
agcagc 366
<210> 40
<211> 366
<212> DNA
<213> 人工序列
<400> 40
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa cacctttagc tttagcacct attgcatggg ctggtttcgt 120
cagagcccgg gcaaagaacg tgaaggcagc ctggcgacca tttatgatgc gagcaccgcg 180
tatgcgggca gcgtgaaagg ccgttttacc attagccgtg ataacagcaa aaacattctg 240
tatctgcaga tgaacaacct gcgtgcggaa gataccgcgg tgtattattg cgcggcggcg 300
cgttattgca tgttttggag ccatccgagc tattggggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 41
<211> 366
<212> DNA
<213> 人工序列
<400> 41
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa cacctttagc tttagcacct attgcatggg ctggtttcgt 120
cagagcccgg gcaaagaacg tgaaggcagc ctggcgacca tttatgatgc gagcaccgcg 180
tatgcgggca gcgtgaaagg ccgttttacc attagcgtgg ataacgcgaa aaacattctg 240
tatctgcaga tgaacaacct gaaaccggaa gataccgcga tgtattattg cgcggcggcg 300
cgttattgca tgttttggag ccatccgagc tattggggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 42
<211> 366
<212> DNA
<213> 人工序列
<400> 42
caggtgcagc tggtggaaag cggcggcggc agcgtgcagg cgggcggcag cctgcgtctg 60
agctgcgcgg cgagcggcaa cacctttagc tttagcacct attgcatggg ctggtttcgt 120
cagagcccgg gcaaagaacg tgaaggcagc ctggcgacca tttatgatgc gagcaccgcg 180
tatgcgggca gcgtgaaagg ccgttttacc attagccgtg ataacgcgaa aaacattctg 240
tatctgcaga tgaacaacct gcgtgcggaa gataccgcgg tgtattattg cgcggcggcg 300
cgttattgca tgttttggag ccatccgagc tattggggcc agggcaccca ggtgaccgtg 360
agcagc 366
<210> 43
<211> 8
<212> PRT
<213> 人工序列
<400> 43
Gly Ile Thr Ala Ser Thr Ser Cys
1 5
<210> 44
<211> 8
<212> PRT
<213> 人工序列
<400> 44
Gly Ile Thr Ser Ser Thr Ala Cys
1 5
<210> 45
<211> 8
<212> PRT
<213> 人工序列
<400> 45
Gly Ile Thr Ser Ser Thr Ser Cys
1 5
<210> 46
<211> 8
<212> PRT
<213> 人工序列
<400> 46
Gly Leu Thr Leu Asn Asp Val Ser
1 5
<210> 47
<211> 10
<212> PRT
<213> 人工序列
<400> 47
Gly Asn Thr Phe Ser Phe Ser Thr Tyr Cys
1 5 10
<210> 48
<211> 10
<212> PRT
<213> 人工序列
<400> 48
Gly Asn Thr Phe Ser Thr Ser Thr Tyr Cys
1 5 10
<210> 49
<211> 6
<212> PRT
<213> 人工序列
<400> 49
Gly Asn Thr Leu Asp Leu
1 5
<210> 50
<211> 7
<212> PRT
<213> 人工序列
<400> 50
Ile Asp Ile Asp Gly Leu Ile
1 5
<210> 51
<211> 7
<212> PRT
<213> 人工序列
<400> 51
Ile Tyr Ser Ser Gly Thr Thr
1 5
<210> 52
<211> 7
<212> PRT
<213> 人工序列
<400> 52
Thr Ile Tyr Asp Ala Ser Thr
1 5
<210> 53
<211> 7
<212> PRT
<213> 人工序列
<400> 53
Thr Ile Tyr Asp Gly Ala Ile
1 5
<210> 54
<211> 7
<212> PRT
<213> 人工序列
<400> 54
Thr Ile Tyr Asp Gly Asn Ile
1 5
<210> 55
<211> 7
<212> PRT
<213> 人工序列
<400> 55
Thr Ile Tyr Asp Gly Ser Ile
1 5
<210> 56
<211> 7
<212> PRT
<213> 人工序列
<400> 56
Thr Ile Tyr Asp Gly Ser Thr
1 5
<210> 57
<211> 15
<212> PRT
<213> 人工序列
<400> 57
Ala Ala Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp
1 5 10 15
<210> 58
<211> 15
<212> PRT
<213> 人工序列
<400> 58
Ala Ala Ala Lys Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp
1 5 10 15
<210> 59
<211> 15
<212> PRT
<213> 人工序列
<400> 59
Ala Ala Ala Arg Tyr Cys Met Phe Trp Ser His Pro Ser Tyr Trp
1 5 10 15
<210> 60
<211> 19
<212> PRT
<213> 人工序列
<400> 60
Ala Ala Lys Val Ser Trp Tyr Gly Arg Trp Tyr Gln Ser Glu Thr Tyr
1 5 10 15
Glu Tyr Trp
<210> 61
<211> 17
<212> PRT
<213> 人工序列
<400> 61
Ala Ala Val Arg Leu Tyr Phe Ser Ser Ser Arg Asn Gln Tyr Lys Tyr
1 5 10 15
Glu
<210> 62
<211> 15
<212> PRT
<213> 人工序列
<400> 62
Ala Ser Ala Lys Tyr Cys Met Phe Trp Ser Asp Pro Ser Tyr Trp
1 5 10 15
<210> 63
<211> 25
<212> PRT
<213> 人工序列
<400> 63
Gln Val Gln Leu Val Glu Ser Glu Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser
20 25
<210> 64
<211> 25
<212> PRT
<213> 人工序列
<400> 64
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Ala Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25
<210> 65
<211> 25
<212> PRT
<213> 人工序列
<400> 65
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25
<210> 66
<211> 25
<212> PRT
<213> 人工序列
<400> 66
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Ala Ser
20 25
<210> 67
<211> 25
<212> PRT
<213> 人工序列
<400> 67
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25
<210> 68
<211> 25
<212> PRT
<213> 人工序列
<400> 68
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25
<210> 69
<211> 17
<212> PRT
<213> 人工序列
<400> 69
Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Glu Val Ala
1 5 10 15
Gly
<210> 70
<211> 17
<212> PRT
<213> 人工序列
<400> 70
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala
1 5 10 15
Ala
<210> 71
<211> 17
<212> PRT
<213> 人工序列
<400> 71
Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ala
1 5 10 15
Gly
<210> 72
<211> 17
<212> PRT
<213> 人工序列
<400> 72
Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Gly Ser Leu
1 5 10 15
Ala
<210> 73
<211> 38
<212> PRT
<213> 人工序列
<400> 73
Ala Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Val Asp Asn
1 5 10 15
Ala Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp
20 25 30
Thr Ala Met Tyr Tyr Cys
35
<210> 74
<211> 38
<212> PRT
<213> 人工序列
<400> 74
Ala Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ser Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35
<210> 75
<211> 38
<212> PRT
<213> 人工序列
<400> 75
Ala Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ala Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35
<210> 76
<211> 38
<212> PRT
<213> 人工序列
<400> 76
Ala Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Val Ser Val Asp Asn
1 5 10 15
Ala Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp
20 25 30
Thr Ala Met Tyr Tyr Cys
35
<210> 77
<211> 38
<212> PRT
<213> 人工序列
<400> 77
Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ala Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35
<210> 78
<211> 38
<212> PRT
<213> 人工序列
<400> 78
Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ser Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35
<210> 79
<211> 38
<212> PRT
<213> 人工序列
<400> 79
Ser Tyr Ala Asp Pro Val Lys Gly Arg Phe Thr Ile Ser Lys Asp Asn
1 5 10 15
Ala Gln Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp
20 25 30
Thr Ala Met Tyr Ser Cys
35
<210> 80
<211> 38
<212> PRT
<213> 人工序列
<400> 80
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35
<210> 81
<211> 38
<212> PRT
<213> 人工序列
<400> 81
Tyr Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
1 5 10 15
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
20 25 30
Thr Ala Val Tyr Tyr Cys
35
<210> 82
<211> 38
<212> PRT
<213> 人工序列
<400> 82
Ser Tyr Ala Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Val Asp Asn
1 5 10 15
Ala Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp
20 25 30
Thr Ala Met Tyr Tyr Cys
35
<210> 83
<211> 38
<212> PRT
<213> 人工序列
<400> 83
Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Lys Asp Asn
1 5 10 15
Ala Gln Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp
20 25 30
Thr Ala Met Tyr Ser Cys
35
<210> 84
<211> 38
<212> PRT
<213> 人工序列
<400> 84
Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Val Asp Asn
1 5 10 15
Ala Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Lys Pro Ala Asp
20 25 30
Thr Ala Met Tyr Tyr Cys
35
<210> 85
<211> 38
<212> PRT
<213> 人工序列
<400> 85
Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Val Asp Asn
1 5 10 15
Ala Lys Asn Ile Leu Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp
20 25 30
Thr Ala Met Tyr Tyr Cys
35
<210> 86
<211> 38
<212> PRT
<213> 人工序列
<400> 86
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn
1 5 10 15
Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp
20 25 30
Ala Ala Met Tyr Tyr Cys
35
<210> 87
<211> 10
<212> PRT
<213> 人工序列
<400> 87
Gly Gln Gly Thr Gln Val Thr Val Ser Ser
1 5 10
Claims (12)
1.IL-5的结合分子，其特征在于，其能特异性结合IL-5且包含至少一个免疫球蛋白单一可变结构域，所述免疫球蛋白单一可变结构域包括互补决定区CDR1、CDR2和CDR3；
其中，CDR1的氨基酸序列选自如SEQ ID NO.43～49所示序列中的任意一种；CDR2的氨基酸序列选自如SEQ ID NO.50～56所示序列中的任意一种；CDR3的氨基酸序列选自如SEQID NO.57～62所示序列中的任意一种。
2.根据权利要求1所述的IL-5的结合分子，其特征在于，所述互补决定区CDR1、CDR2和CD R3的氨基酸序列如(1)～(13)中任一项所示；
(1)如SEQ ID No.43、56和58所示；
(2)如SEQ ID No.49、51和60所示；
(3)如SEQ ID No.47、56和57所示；
(4)如SEQ ID No.45、54和57所示；
(5)如SEQ ID No.46、50和61所示；
(6)如SEQ ID No.47、56和62所示；
(7)如SEQ ID No.48、56和57所示；
(8)如SEQ ID No.45、53和57所示；
(9)如SEQ ID No.44、55和57所示；
(10)如SEQ ID No.43、56和59所示；
(11)如SEQ ID No.43、52和59所示；
(12)如SEQ ID No.47、56和59所示；
(13)如SEQ ID No.47、52和59所示；
优选地，所述免疫球蛋白单一可变结构域还包括骨架区，所述骨架区包括FR1、FR2、FR3和FR4；
其中，所述FR1的氨基酸序列选自如SEQIDNo.63～68所示序列中的任意一种；所述FR2的氨基酸序列选自如SEQIDNo.69～72所示序列中的任意一种；所述FR3的氨基酸序列选自如SEQIDNo.73～86所示序列中的任意一种；所述FR4的氨基酸序列如SEQIDNo.87所示；
优选地，所述免疫球蛋白单一可变结构域的骨架区FR1、FR2和FR3的序列如(14)～(28)中任一项所示；
(14)如SEQ ID No.65、72和85所示；
(15)如SEQ ID No.65、72和82所示；
(16)如SEQ ID No.64、71和86所示；
(17)如SEQ ID No.65、72和73所示；
(18)如SEQ ID No.65、72和84所示；
(19)如SEQ ID No.66、69和83所示；
(20)如SEQ ID No.68、72和76所示；
(21)如SEQ ID No.66、69和79所示；
(22)如SEQ ID No.63、72和85所示；
(23)如SEQ ID No.67、70和80所示；
(24)如SEQ ID No.65、72和78所示；
(25)如SEQ ID No.65、72和77所示；
(26)如SEQ ID No.67、70和81所示；
(27)如SEQ ID No.65、72和74所示；
(28)如SEQ ID No.65、72和75所示。
3.根据权利要求2所述的IL-5的结合分子，其特征在于，所述免疫球蛋白单一可变结构域为VHH；
优选地，所述VHH的氨基酸序列选自如SEQ ID No.1～12所示序列中的任意一种；
优选地，所述VHH为人源化的VHH；
优选地，所述人源化的VHH的序列选自如SEQ ID No.13～21所示序列中的任意一种。
4.根据权利要求1-3任一项所述的IL-5的结合分子，其特征在于，所述结合分子还包含免疫球蛋白Fc区，所述免疫球蛋白Fc区与VHH相连。
5.根据权利要求4所述的IL-5的结合分子，其特征在于，所述免疫球蛋白Fc区是人免疫球蛋白Fc区；
优选地，所述人免疫球蛋白Fc区是人IgG4的Fc区。
6.分离的核苷酸，其特征在于，其编码如权利要求1-5任一项所述的IL-5的结合分子；
优选地，所述核苷酸的序列选自如SEQ ID No.22～42所示序列中的任意一种。
7.重组载体，其特征在于，其含有如权利要求6所述的分离的核苷酸。
8.宿主细胞，其特征在于，其含有如权利要求7所述的重组载体。
9.IL-5的结合分子的制备方法，其特征在于，其包括培养如权利要求8所述的宿主细胞，获得IL-5的结合分子。
10.用于结合IL-5蛋白的偶联物，其特征在于，其包括偶联组分，以及如权利要求1～5任一项所述的IL-5的结合分子；所述偶联组分与所述结合分子偶联；所述偶联组分包括用于检测的标记物和/或化合物；
优选地，所述用于检测的标记物为放射性元素。
11.用于检测IL-5蛋白的试剂盒，其特征在于，其包括如权利要求1～5任一项所述的IL-5的结合分子。
12.如权利要求1～5任一项所述的IL-5的结合分子在制备用于治疗疾病且以IL-5为靶点的药物中的应用；
优选地，所述疾病选自：哮喘、过敏性皮炎、湿疹、关节炎、疱疹、慢性原发性荨麻疹、硬皮病、肥大性瘢痕、慢性阻塞性肺疾病、特应性皮炎、特发性肺纤维化、川崎病、镰状细胞病、格雷夫斯氏病、舍格伦综合征、自体免疫淋巴组织增生性综合征、自体免疫性溶血性贫血、巴雷特食管、自体免疫葡萄膜炎、结核病和肾病中的任意一种。
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311645148.6A CN117903303A (zh) | 2020-08-20 | 2020-08-20 | Il-5的结合分子及其应用 |
| CN202010843501.1A CN114075282B (zh) | 2020-08-20 | 2020-08-20 | Il-5的结合分子及其制备方法和应用 |
| JP2022580478A JP2023532491A (ja) | 2020-08-20 | 2021-02-24 | Ｉｌ－５結合分子、その調製方法及びその使用 |
| US18/001,818 US20230235039A1 (en) | 2020-08-20 | 2021-02-24 | Il-5 binding molecule, preparation method therefor, and use thereof |
| KR1020237006340A KR20230044256A (ko) | 2020-08-20 | 2021-02-24 | Il-5의 결합 분자 및 그 제조 방법과 응용 |
| PCT/CN2021/077650 WO2022037031A1 (zh) | 2020-08-20 | 2021-02-24 | Il-5的结合分子及其制备方法和应用 |
| BR112023000272A BR112023000272A2 (pt) | 2020-08-20 | 2021-02-24 | Molécula de ligação de il-5, método de preparação da mesma e uso da mesma |
| EP21857136.2A EP4151649A1 (en) | 2020-08-20 | 2021-02-24 | Il-5 binding molecule, preparation method therefor, and use thereof |
| CA3183124A CA3183124A1 (en) | 2020-08-20 | 2021-02-24 | Il-5 binding molecule, preparation method therefor, and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010843501.1A CN114075282B (zh) | 2020-08-20 | 2020-08-20 | Il-5的结合分子及其制备方法和应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311645148.6A Division CN117903303A (zh) | 2020-08-20 | 2020-08-20 | Il-5的结合分子及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114075282A true CN114075282A (zh) | 2022-02-22 |
| CN114075282B CN114075282B (zh) | 2024-01-02 |
Family
ID=80281812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010843501.1A Active CN114075282B (zh) | 2020-08-20 | 2020-08-20 | Il-5的结合分子及其制备方法和应用 |
| CN202311645148.6A Pending CN117903303A (zh) | 2020-08-20 | 2020-08-20 | Il-5的结合分子及其应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311645148.6A Pending CN117903303A (zh) | 2020-08-20 | 2020-08-20 | Il-5的结合分子及其应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230235039A1 (zh) |
| EP (1) | EP4151649A1 (zh) |
| JP (1) | JP2023532491A (zh) |
| KR (1) | KR20230044256A (zh) |
| CN (2) | CN114075282B (zh) |
| BR (1) | BR112023000272A2 (zh) |
| CA (1) | CA3183124A1 (zh) |
| WO (1) | WO2022037031A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023226617A1 (zh) * | 2022-05-23 | 2023-11-30 | 南京融捷康生物科技有限公司 | 一种稳定的抗体制剂 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010354A1 (en) * | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
| WO2003085089A2 (en) * | 2002-03-29 | 2003-10-16 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| CN111040035A (zh) * | 2019-12-31 | 2020-04-21 | 南京融捷康生物科技有限公司 | 针对il-17ra蛋白的抗体及其制备方法和应用 |
| WO2020119728A1 (zh) * | 2018-12-12 | 2020-06-18 | 尚华科创投资管理（江苏）有限公司 | 抗人白细胞介素5(il-5)单克隆抗体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6056957A (en) | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| NZ599144A (en) * | 2006-09-08 | 2013-10-25 | Abbott Lab | Interleukin -13 binding proteins |
| MX2014001883A (es) * | 2011-08-17 | 2014-05-27 | Glaxo Group Ltd | Proteinas y peptidos modificados. |
| GB201802487D0 (en) * | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
-
2020
- 2020-08-20 CN CN202010843501.1A patent/CN114075282B/zh active Active
- 2020-08-20 CN CN202311645148.6A patent/CN117903303A/zh active Pending
-
2021
- 2021-02-24 CA CA3183124A patent/CA3183124A1/en active Pending
- 2021-02-24 EP EP21857136.2A patent/EP4151649A1/en active Pending
- 2021-02-24 US US18/001,818 patent/US20230235039A1/en active Pending
- 2021-02-24 WO PCT/CN2021/077650 patent/WO2022037031A1/zh unknown
- 2021-02-24 BR BR112023000272A patent/BR112023000272A2/pt unknown
- 2021-02-24 KR KR1020237006340A patent/KR20230044256A/ko unknown
- 2021-02-24 JP JP2022580478A patent/JP2023532491A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010354A1 (en) * | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
| WO2003085089A2 (en) * | 2002-03-29 | 2003-10-16 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| CA2479927A1 (en) * | 2002-03-29 | 2003-10-16 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| WO2020119728A1 (zh) * | 2018-12-12 | 2020-06-18 | 尚华科创投资管理（江苏）有限公司 | 抗人白细胞介素5(il-5)单克隆抗体及其应用 |
| CN111040035A (zh) * | 2019-12-31 | 2020-04-21 | 南京融捷康生物科技有限公司 | 针对il-17ra蛋白的抗体及其制备方法和应用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023226617A1 (zh) * | 2022-05-23 | 2023-11-30 | 南京融捷康生物科技有限公司 | 一种稳定的抗体制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023000272A2 (pt) | 2023-03-14 |
| JP2023532491A (ja) | 2023-07-28 |
| EP4151649A1 (en) | 2023-03-22 |
| CN117903303A (zh) | 2024-04-19 |
| WO2022037031A1 (zh) | 2022-02-24 |
| CN114075282B (zh) | 2024-01-02 |
| KR20230044256A (ko) | 2023-04-03 |
| CA3183124A1 (en) | 2022-02-24 |
| US20230235039A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108251431B (zh) | 双载体系统及其用途 | |
| KR20150032337A (ko) | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 | |
| CN111057148B (zh) | 针对牛血清白蛋白bsa的单域抗体及其衍生蛋白 | |
| CN111018985B (zh) | 针对牛血清白蛋白bsa的单域抗体的应用 | |
| CN111040035B (zh) | 针对il-17ra蛋白的抗体及其制备方法和应用 | |
| CN116162160A (zh) | 一种抗il-6的单域抗体及其用途 | |
| CN111690066A (zh) | 抗IL-4Rα的单域抗体以及应用和药物 | |
| CN113480657B (zh) | 针对her2的单域抗体及其衍生蛋白和应用 | |
| CN114075282B (zh) | Il-5的结合分子及其制备方法和应用 | |
| CN116162161A (zh) | 一种抗il-6r的单域抗体及其用途 | |
| CN113831411B (zh) | 针对l1cam的单域抗体及其衍生蛋白和应用 | |
| CN111057154B (zh) | 基于驼源Fc片段的免疫原的制备及应用 | |
| CN115181182A (zh) | 一种人源化的抗cd25的单域抗体及其应用 | |
| CN116262786A (zh) | 针对folr1的单域抗体及其衍生蛋白和应用 | |
| RU2811518C1 (ru) | Il-5-связывающая молекула, способ ее получения и ее применение | |
| CN114591432B (zh) | 抗TNFα的单域抗体及其用途 | |
| CN114920838B (zh) | 一种抗il-17a的单域抗体及其用途 | |
| CN114044826B (zh) | 针对EGFRvIII的单域抗体及其衍生蛋白和应用 | |
| CN116621984A (zh) | 一种抗cd155的单域抗体及其用途 | |
| CN116715770A (zh) | 一种抗ephA2的单域抗体及其用途 | |
| CN116143926A (zh) | 一种抗IL1RAcP的单域抗体及其用途 | |
| CN116375875A (zh) | 一种抗lag3的单域抗体及其用途 | |
| CN117327176A (zh) | 一种抗tslp的单域抗体及其用途 | |
| CN117820481A (zh) | 新型抗体分子及其制药用途 | |
| CN117843804A (zh) | 单域抗体串联分子及其序列、产品、制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |